Profile data is unavailable for this security.
About the company
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
- Revenue in USD (TTM)0.00
- Net income in USD-110.78m
- Incorporated2014
- Employees107.00
- LocationOric Pharmaceuticals Inc240 E. Grand Ave, 2nd FloorSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 388-5600
- Fax+1 (302) 655-5049
- Websitehttp://oricpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Arcturus Therapeutics Holdings Inc | 163.87m | -71.96m | 645.77m | 180.00 | -- | 2.50 | -- | 3.94 | -2.68 | -2.68 | 6.11 | 9.56 | 0.40 | -- | 12.19 | 910,366.70 | -17.57 | -19.66 | -22.59 | -24.90 | -- | -- | -43.92 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
Humacyte Inc | 0.00 | -139.66m | 649.27m | 183.00 | -- | -- | -- | -- | -1.26 | -1.26 | 0.00 | -0.237 | 0.00 | -- | -- | 0.00 | -91.17 | -- | -100.75 | -- | -- | -- | -- | -- | -- | -40.08 | -- | -- | -100.00 | -- | -825.83 | -- | -- | -- |
Olema Pharmaceuticals Inc | 0.00 | -109.63m | 664.29m | 80.00 | -- | 2.92 | -- | -- | -2.06 | -2.06 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -50.73 | -30.06 | -56.10 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
Annexon Inc | 0.00 | -115.16m | 664.56m | 71.00 | -- | 1.84 | -- | -- | -1.22 | -1.22 | 0.00 | 3.42 | 0.00 | -- | -- | 0.00 | -36.04 | -44.06 | -38.13 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
Astria Therapeutics Inc | 0.00 | -93.24m | 669.77m | 59.00 | -- | 2.59 | -- | -- | -2.30 | -2.30 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -32.43 | -64.48 | -33.78 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
ORIC Pharmaceuticals Inc | 0.00 | -110.78m | 677.91m | 107.00 | -- | 2.15 | -- | -- | -1.76 | -1.76 | 0.00 | 4.47 | 0.00 | -- | -- | 0.00 | -35.69 | -33.92 | -37.77 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
SS Innovations International Inc | 14.41m | -23.68m | 681.25m | 239.00 | -- | 40.11 | -- | 47.28 | -0.1396 | -0.1396 | 0.0847 | 0.0995 | 0.6003 | 2.28 | 5.08 | 60,293.01 | -98.66 | -161.38 | -216.15 | -449.76 | 28.42 | -79.79 | -164.35 | -495.77 | 0.9128 | -45.39 | 0.4172 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
Tourmaline Bio Inc | 0.00 | -35.69m | 685.39m | 44.00 | -- | 2.03 | -- | -- | -2.54 | -2.54 | 0.00 | 13.19 | 0.00 | -- | -- | 0.00 | -14.16 | -- | -14.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
Ironwood Pharmaceuticals, Inc. | 400.57m | 9.21m | 686.88m | 267.00 | 99.51 | -- | 74.49 | 1.71 | 0.0432 | 0.0432 | 2.43 | -2.01 | 0.8021 | -- | 4.52 | 1,500,244.00 | 1.44 | -4.54 | 2.21 | -5.20 | -- | -- | 1.79 | -7.81 | -- | 4.60 | 2.07 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
Mineralys Therapeutics Inc | 0.00 | -119.67m | 690.21m | 28.00 | -- | 2.38 | -- | -- | -2.71 | -2.71 | 0.00 | 5.84 | 0.00 | -- | -- | 0.00 | -39.26 | -- | -41.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
Terns Pharmaceuticals Inc | 0.00 | -95.90m | 697.99m | 66.00 | -- | 2.66 | -- | -- | -1.31 | -1.31 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -36.84 | -41.34 | -38.72 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
Capricor Therapeutics Inc | 27.15m | -27.95m | 704.47m | 101.00 | -- | 60.20 | -- | 25.95 | -0.9302 | -0.9302 | 0.9072 | 0.3596 | 0.6443 | -- | 59.18 | 268,833.90 | -66.31 | -54.12 | -208.71 | -75.13 | -- | -- | -102.93 | -316.25 | -- | -- | 0.2269 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
Lenz Therapeutics Inc | 0.00 | -72.31m | 708.86m | 6.00 | -- | 3.45 | -- | -- | -9.45 | -9.45 | 0.00 | 7.46 | 0.00 | -- | -- | 0.00 | -29.53 | -- | -30.84 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 5.02m | 7.45% |
Viking Global Investors LPas of 31 Mar 2024 | 4.00m | 5.93% |
Alkeon Capital Management LLCas of 31 Mar 2024 | 3.70m | 5.49% |
EcoR1 Capital, LLCas of 31 Mar 2024 | 3.42m | 5.07% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.89m | 4.29% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.84m | 4.21% |
Commodore Capital LPas of 31 Mar 2024 | 2.00m | 2.97% |
Silverbay Capital Management LLCas of 31 Mar 2024 | 1.82m | 2.70% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.72m | 2.55% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 1.55m | 2.29% |